Chemoembolization for Liver Cancer Patients with Decompensate Liver Function:Strategy and Philosophy
XIA Jing-lin
Abstract：Liver cancer with decompensated liver function is conventionally contraindication for chemoembolization. Liver dysfunction including jaundice, alanine aminotransferase elevation, hypoproteinemia with ascites, hypersplenism with leukocyte and/or thrombocytopenia. Based on long-term practice, this paper proposes the strategy of chemoembolization for liver cancer patients with decompensated liver function. Firstly, modify the chemoembolization method ( Dose-reduced chemo-embolization) ,which means reduce the dose of chemotherapeutic drugs and the dosage of embolic agent remains normal. Sec-ondly, differential the causes of liver dysfunction, such as obstructive jaundice caused by tumor compression and elevated ala-nine aminotransferase caused by tumor. For patient like these, chemoembolization should be the first choice, rather than re-duce the jaundice or protect the liver function. For patients with ascites caused by hypoproteinemia, leukopenia and/or throm-bocytopenia caused by hypersplenism, the first issue is control the tumor rather than adjuvant therapy.
Keywords：Liver neoplasmsHepatic insufficiencyRadiographyinterventionalChemotherapycancerregional perfusion
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1-5 )